COLORADO SPRINGS, Colo. (KKTV) - A southern Colorado man is sharing how a blood test helped him catch his second cancer ...
Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge ...
Natera reported gross margin of just under 65% in Q1, above the company’s prior midpoint expectation of 64% for full-year 2026. Chapman said rapid volume growth created a roughly 2 percentage point ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration ...
Molecular residual disease tests analyze blood samples for evidence of cancer cells lingering in the body after treatment with surgery or chemotherapy. Traditional approaches to monitoring the disease ...
NEW YORK – Natera and Diakonos Oncology on Friday announced a collaboration to use Natera's circulating tumor DNA (ctDNA) assay Signatera to longitudinally assess molecular response in Diakonos' Phase ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first ...
During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41.
Zacks Investment Research on MSN
NTRA's Signatera CDx wins FDA nod in muscle-invasive bladder cancer
Natera, Inc. NTRA recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results